- Home
- TPIC vs GANX Comparison
TPIC vs GANX Comparison
Compare TPIC & GANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TPIC
- GANX
- Stock Information
- Founded
- TPIC 1968
- GANX 2017
- Country
- TPIC United States
- GANX United States
- Employees
- TPIC N/A
- GANX N/A
- Industry
- TPIC Industrial Machinery/Components
- GANX Biotechnology: Pharmaceutical Preparations
- Sector
- TPIC Industrials
- GANX Health Care
- Exchange
- TPIC Nasdaq
- GANX Nasdaq
- Market Cap
- TPIC 58.4M
- GANX 51.8M
- IPO Year
- TPIC 2016
- GANX 2021
- Fundamental
- Price
- TPIC $0.79
- GANX $1.50
- Analyst Decision
- TPIC Hold
- GANX Strong Buy
- Analyst Count
- TPIC 7
- GANX 5
- Target Price
- TPIC $1.68
- GANX $8.20
- AVG Volume (30 Days)
- TPIC 475.4K
- GANX 260.5K
- Earning Date
- TPIC 08-11-2025
- GANX 08-07-2025
- Dividend Yield
- TPIC N/A
- GANX N/A
- EPS Growth
- TPIC N/A
- GANX N/A
- EPS
- TPIC N/A
- GANX N/A
- Revenue
- TPIC $1,373,242,000.00
- GANX N/A
- Revenue This Year
- TPIC $10.73
- GANX N/A
- Revenue Next Year
- TPIC $5.56
- GANX N/A
- P/E Ratio
- TPIC N/A
- GANX N/A
- Revenue Growth
- TPIC 3.05
- GANX N/A
- 52 Week Low
- TPIC $0.64
- GANX $0.89
- 52 Week High
- TPIC $5.15
- GANX $3.19
- Technical
- Relative Strength Index (RSI)
- TPIC 39.96
- GANX 37.47
- Support Level
- TPIC $0.78
- GANX $1.46
- Resistance Level
- TPIC $0.91
- GANX $1.72
- Average True Range (ATR)
- TPIC 0.07
- GANX 0.12
- MACD
- TPIC 0.00
- GANX -0.01
- Stochastic Oscillator
- TPIC 27.67
- GANX 7.37
About TPIC TPI Composites Inc.
TPI Composites Inc is engaged in manufacturing composite wind blades. The company operates in wind energy and transportation industries where it manufactures structures for a bus, rail, theme parks, and trucks. Geographically the segments are divided into the U.S, Asia, Mexico, EMEA and India where the Mexico segment derives a majority of revenue.
About GANX Gain Therapeutics Inc.
Gain Therapeutics Inc is a biotechnology company developing novel small molecule therapeutics to treat diseases across several therapeutic areas, including, lysosomal storage disorders, central nervous system disorders, metabolic disorders, and oncology. The company's clinical-stage product candidate, GT-02287, is being developed for the treatment of GBA1 Parkinson's disease. The company uses its computational target and drug discovery platform, Magellan, to discover novel allosteric binding sites on proteins implicated in disease and to identify proprietary small molecules that bind these sites to modulate protein function and treat the underlying cause of the disease. Geographically, the company operates in Switzerland, Spain, the United States, and Australia.